- HIV - stands for Human Immunodeficiency Virus. A virus that weakens a patient’s immune system over time.
- HIV-1 - the most common type of HIV worldwide.
- CD4+ T-cell - a type of cell that helps fight infections. Called CD4+ because of a type of receptor on the surface of the cell
- combination antiretroviral therapy - the combination of medicines, or regimen, used to treat HIV infection
- R5 HIV 1 This type of HIV uses the coreceptor CCR5 (R5 for short) as a coreceptor to blind to and infect human cells.
- T Cell Count measurement of the amount of T-cells found in a sample of blood.
- CCR5-tropic HIV-1 - the type of HIV-1 that uses the CCR5 coreceptor to attach to CD4+ T-cells.
- CD4+ T-cell count - the number of CD4+ T-cells in every cubic millimeter of blood.
- Coreceptor – on the surface of CD4+ T-cells; used by HIV, along with the CD4 receptor, to attach to CD4+ T-cells.
- Tropism – refers to the type of coreceptor that HIV uses to attach to CD4+ T-cells.
- Tropism test or tropism assay – test done to determine which type of coreceptor a patient’s HIV uses to attach to a CD4+ T-cell.
- AIDS – stands for Acquired Immunodeficiency Syndrome. The most severe phase of HIV infection. People with AIDS have such badly damaged immune systems that they get an increasing number of severe illnesses, called opportunistic illnesses
- Opportunistic infections - infections that occur more frequently and are more severe in individuals with weakened immune systems, including people with HIV
Whether you have HIV or provide care for someone who does, there’s nothing easy about living with the condition. Learning more about HIV-1 and the different ways to treat it may help.
Thank you for visiting the site for SELZENTRY. We’d like to help you learn more.
SELZENTRY is an HIV-1 medication that is used with other HIV-1 medications to treat only CCR5-tropic HIV-1 in adults or children 2 years of age or older. Though you may already know a lot about HIV, it's possible you may not be familiar with what CCR5-tropic means. Please keep reading to learn more and discover what's different about SELZENTRY.
Each patient’s HIV-1 may be different
One important way every patient's virus is different is in how it attaches to and makes its way into the CD4+ T-cell. For this to happen, HIV-1 attaches to what is called a coreceptor.
There are 2 different coreceptors: CCR5 and CXCR4
Some HIV-1 will use only 1 of these coreceptors, and some can use either. Some patients may be infected with a mixture of viruses. This can be seen in the pictures below.
Viruses that use only CCR5 are called CCR5-tropic, and viruses that use only CXCR4 are called CXCR4-tropic. If the virus can use either coreceptor, it is called dual-tropic.
SELZENTRY (maraviroc) is only used to treat CCR5-tropic HIV-1. SELZENTRY is not approved or effective for patients infected with CXCR4-tropic, dual-tropic, or mixed-tropic HIV-1.
SELZENTRY helps defend your CD4+ T-cells against CCR5-tropic HIV-1
Here's how it works: SELZENTRY belongs to a class of HIV-1 medicines called CCR5 coreceptor antagonists. In fact, it's the only CCR5 coreceptor antagonist available. SELZENTRY attaches to a specific coreceptor on CD4+ T-cells called CCR5. This helps to inhibit CCR5-tropic HIV-1 from entering CD4+ T-cells.
SELZENTRY must be used in combination with other HIV-1 meds prescribed to you.
When used with other HIV-1 medications:
- SELZENTRY may reduce the amount of HIV-1 in your blood (viral load)
- SELZENTRY may increase the number of CD4+ T-cells in your body
Could SELZENTRY be part of your treatment plan?
There is a screening test your healthcare provider will perform to see if the HIV-1 you are infected with attaches to the CCR5 coreceptor. This is called a tropism test or tropism assay. If your virus attaches only to the CCR5 coreceptor, then SELZENTRY may be an option to include in your treatment plan along with other HIV-1 medicines. Talk with your doctor to see if SELZENTRY is something you may want to consider.
About ViiV Healthcare
ViiV Healthcare was formed in November 2009 with a 100% focus on HIV and a commitment to deliver new options for the care and treatment of HIV. We are proud of our contribution over the past five years to people living with HIV. Looking forward, we are committed to continuing our efforts to address the challenges of HIV treatment and care with the ultimate aspiration of one day developing a possible cure for HIV.